NASDAQ$JYNT

The Joint Corp · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

The Joint Corp. reported Q4 2025 revenue of $15.2M with consolidated net income of $1.0M and diluted EPS of $0.07.

For the quarter ended December 31, 2025, Joint posted revenue of $15.2 million, up 3.1% year over year, with consolidated net income of $1.0 million versus $18,000 a year ago and diluted EPS of $0.07. System-wide sales fell 3.9% and comp sales were (3.8)% as refranchising progressed. Full-year 2025 revenue was $54.9 million with consolidated net income of $2.9 million; the company repurchased 1.1 million shares for $9.0 million in Q4.

  • Q4 revenue of $15.2M (+3.1% YoY) with consolidated net income of $1.0M and EPS of $0.07.
  • System-wide sales of $139.6M declined 3.9% YoY; comp sales were (3.8)%.
  • Adjusted EBITDA from consolidated operations rose 7.8% to $3.6M in Q4.
  • Refranchising advanced with 41 clinics refranchised since early 2025; 48 company-owned clinics remain.
  • 2026 guidance: system-wide sales $519M–$552M and consolidated Adjusted EBITDA $12.5M–$13.5M.

Headline financials

Total Revenue

$15.2M

Previous: $14.4M+5.6%
EPS (adj)

$0.07

Previous: $0.06+16.7%
Net Income

$1M

Previous: $986K+1.4%

Revenue & EPS history

The Joint · Revenue · Quarterly

$15.2M

Q4 2025+5.6%vs Q4 2024
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Forward guidance

For 2026, management guided system-wide sales of $519–552 million, comp sales of (3)% to 3%, consolidated Adjusted EBITDA of $12.5–13.5 million, and 30–35 new franchised openings excluding refranchised clinics.

Tailwinds

  • Joint 2.0 refranchising path targets a capital-light pure-play franchisor model by year-end 2026.
  • Adjusted EBITDA guidance midpoint is roughly flat versus $13.0M in 2025 despite macro headwinds.

Headwinds

  • Comp sales remained negative in Q4 and full-year 2025 at (0.4)%.
  • System-wide sales guidance midpoint implies potential decline from 2025's $532.4M.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

+1.5%

Avg return

Earnings day

+3.3%

Avg return

5 days after

+3.8%

Avg return

30 days after

53%

25 / 47 earnings

Positive

+26.0%

Q1 2024

Best reaction

-42.3%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.5%-2.2%-6.0%
Q4 2025+2.0%+1.9%+6.3%
Q3 2025-3.9%+4.6%+6.1%
Q1 2025-5.0%-5.2%+14.1%
Q4 2024+4.6%+17.9%-1.3%
Q3 2024-2.8%-1.7%-3.1%
Q2 2024-5.1%-3.6%-8.7%
Q1 2024+26.0%+26.1%+17.4%
Q4 2023+25.7%+29.8%+34.8%
Q3 2023+1.3%+4.6%+15.1%
Q2 2023+1.8%-0.2%-14.6%
Q1 2023-3.1%-2.2%-11.2%
Q4 2022+2.3%+1.4%-1.2%
Q3 2022-4.6%-3.3%+1.6%
Q2 2022+15.2%+7.8%-9.6%
Q1 2022-42.3%-43.6%-46.2%
Q4 2021-9.9%-20.8%-24.7%
Q3 2021+5.8%+8.6%-21.8%
Q2 2021+18.9%+17.8%+22.0%
Q1 2021-4.5%-6.8%+28.2%
Q4 2020-10.0%-14.9%-7.0%
Q3 2020+7.1%+28.5%+35.2%
Q2 2020+13.5%+15.1%+23.7%
Q1 2020+9.9%+8.8%+35.6%
Q4 2019-3.0%-10.8%-42.2%
Q3 2019-3.6%-10.3%-13.1%
Q2 2019-0.1%+0.0%-6.2%
Q1 2019+8.7%+4.4%-7.2%
Q4 2018+12.6%+21.5%+42.4%
Q3 2018+3.8%+5.5%+0.5%
Q2 2018+8.5%+3.9%+2.8%
Q1 2018-3.0%+1.8%+1.9%
Q4 2017+8.2%+23.7%+35.9%
Q3 2017+16.2%+23.0%+8.6%
Q2 2017+3.6%+2.7%+34.5%
Q1 2017+7.3%+2.6%-1.3%
Q4 2016-15.3%-11.4%-15.8%
Q3 2016+3.7%+6.1%-6.5%
Q2 2016-0.5%-0.9%+28.9%
Q1 2016-0.0%
Q4 2015-21.5%
Q3 2015-6.1%
Q2 2015+1.3%
Q1 2015+6.2%
Q4 2014+4.0%
Q3 2014-1.6%
Q3 2013-1.6%
Q1 2014
Q4 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro